DIA MASC 2025

Medical Affairs 2.0: GenAI as the Catalyst for Change in Writing, MedComms, and Field Strategy

Digital and AI were hot topics underpinning many of the conversations at the DIA’s Medical Affairs and Scientific Communications (DIA MASC) forum I attended in March 2025, along with a focus on how we can utilize these tools to achieve impactful, engaging, and scientifically accurate communications that resonate with healthcare providers (HCPs) and patients. Along…...
Read More

Top Stories

Biopharma 2025 Trends

Biopharma Trends 2025: 3 Things to Know Right Now

The global business climate is ever-evolving, and 2025 looks...
AI in Medical Affairs & Medical Communications

Science, AI, and Human Ingenuity Converge to

Today, we're witnessing an unprecedented convergence of...

The Paradigm Shift from Traditional Scientific

In the rapidly evolving biopharma landscape, the approach to...
Plain Language Clinical Trial Summaries

Why Do Plain Language Clinical Trial Summaries Matter?

Did you know that the European Medicines Agency’s Clinical Trials Regulation comes into effect on...
Leveraging technology for patient centricity

Leveraging Technology to Enhance Customer Experience – A 3-Pronged Approach for Medical Affairs

As digital technology changes everything from how drugs are discovered to how healthcare is delivered...
diversity and inclusion

Promoting Diversity and Inclusion in Clinical Trials – New England Journal of Medicine’s New Policy

Read this update on how the New England Journal of Medicine is trying to promote...
Plain language summaries

3 Interesting Facts about Plain Language Summaries

Did you know these 3 facts about plain language summaries?...

World Patient Safety Day September 17, 2021 – Safe Maternal and Newborn Care

This World Patient Safety Day, let's make maternal and newborn care a global health priority...
Clinical Trial Pain Points

Pharma, Physician, and Patient Pain Points Regarding Clinical Trials

Pharma, physicians, and patients consistently face challenges related to clinical trials. Here's a quick look...

Learn more ABOUT our company.